Details of the Drug Combination

General Information of Drug Combination (ID: DCXSO0L)

• Drug Combination Name: Hepzato + Terameprocol
• Indication: Invasive ductal carcinoma; Status: Investigative [1]
• Component Drugs:
  Hepzato (DM2AZPP): N.A.
  Terameprocol (DMC3P45): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: HS 578T
  Zero Interaction Potency (ZIP) Score: 12.19
  Bliss Independence Score: 11.62
  Loewe Additivity Score: 7.6
  LHighest Single Agent (HSA) Score: 7.87

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Hepzato

Disease Entry	ICD 11	Status	REF
Uveal Melanoma	2D0Y	Phase 3	[2]

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[3]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DCUD1D2	HL-60(TB)	Investigative	[4]
Adult T acute lymphoblastic leukemia	DC6S3XJ	MOLT-4	Investigative	[4]
Anaplastic large cell lymphoma	DC7DHX3	SR	Investigative	[4]
Astrocytoma	DC4XWNC	U251	Investigative	[4]
Childhood T acute lymphoblastic leukemia	DCFBNEA	CCRF-CEM	Investigative	[4]
Chronic myelogenous leukemia	DCK8IHH	K-562	Investigative	[4]
Clear cell renal cell carcinoma	DC74FIE	A498	Investigative	[4]
Clear cell renal cell carcinoma	DCX12ZO	CAKI-1	Investigative	[4]
Glioblastoma	DCVMJY8	SNB-75	Investigative	[4]
Glioma	DCL6PM8	SF-539	Investigative	[4]
Papillary renal cell carcinoma	DC0HL1I	ACHN	Investigative	[4]
Plasma cell myeloma	DCLI4ZC	RPMI-8226	Investigative	[4]
Carcinoma	DCFCD95	RXF 393	Investigative	[1]
Carcinoma	DCJAFQX	MCF7	Investigative	[1]
Colon carcinoma	DCHXDHA	KM12	Investigative	[1]
Adenocarcinoma	DCRLWII	DU-145	Investigative	[5]
Adenocarcinoma	DCAOI22	OVCAR3	Investigative	[5]
Adenocarcinoma	DC68ZAG	NCIH23	Investigative	[5]
Adenocarcinoma	DCZ5PNP	HCC-2998	Investigative	[5]
Adenocarcinoma	DCOZG66	HT29	Investigative	[5]
Amelanotic melanoma	DCOSCEX	MDA-MB-435	Investigative	[5]
Cutaneous melanoma	DCMHZN5	SK-MEL-5	Investigative	[5]
High grade ovarian serous adenocarcinoma	DCO3U9J	OVCAR-8	Investigative	[5]
High grade ovarian serous adenocarcinoma	DCH88QQ	OVCAR-5	Investigative	[5]
High grade ovarian serous adenocarcinoma	DC7GGYG	NCI\\/ADR-RES	Investigative	[5]
Lung adenocarcinoma	DCGA0HM	HOP-62	Investigative	[5]
Lung adenocarcinoma	DC4RH99	EKVX	Investigative	[5]
Lung adenocarcinoma	DC7QPNF	NCI-H522	Investigative	[5]
Malignant melanoma	DCP7VOU	UACC62	Investigative	[5]
Melanoma	DC7ZBXV	UACC-257	Investigative	[5]
Non-small cell lung carcinoma	DCVEPHT	HOP-92	Investigative	[5]

References

• [1] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [2] ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
• [3] Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.